This page shows the latest Sparsentan news and features for those working in and with pharma, biotech and healthcare.
Now, the company says a phase II trial of sparsentan in focal segmental glomerulosclerosis (FSG), a rare disease characterised by progressive scarring of the kidneys that often leads to kidney failure, ... Sparsentan was brought into Retrophin's pipeline
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Cegedim Health Data provides Real World Data and Evidence services to enable advancements in patient outcomes. With a data history...